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bilities for CHD events were derived from the Framingham risk
formulae. Baseline cohort characteristics and Niaspan® treat-
ment effects were taken from the ARBITER II study. Patients
with persistently low HDL-c (<1.03 mmol/L) on statin treatment
received either add-on Niaspan® 1g daily or continued statin
monotherapy. Direct costs (2004 Euros) were accounted (car-
diovascular disease and treatment costs). Annual discount rates
of 5% (Germany) and 3.5% (UK) were applied to clinical out-
comes and costs. Undiscounted life expectancy (LE) was also cal-
culated. Sensitivity analyses were performed. RESULTS: A total
of 53.75% of patients were projected to have persistently low
HDL-c levels after statin treatment. In these patients mean undis-
counted LE of 16.12 years and 15.85 years were projected for
the Niaspan® and statin monotherapy arms respectively. Lifetime
direct medical costs were higher by €3563 in Germany and by
£2820 in the UK with addition of Niaspan®. Incremental cost-
effectiveness ratios based on discounted LE were €26,624 per life
year gained in Germany and £17,262 in the UK for statin plus
Niaspan® versus statin monotherapy. Results were most sensitive
to the gender distribution, as women have a lower risk of CHD
events. CONCLUSIONS: In patients with dyslipidemia and per-
sistently low HDL-c, addition of Niaspan® to statin therapy was
projected to be cost-effective compared to statin monotherapy in
Germany and the UK.
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OBJECTIVES: To estimate the medical costs directly related to
the Metabolic Syndrome (MS) in Italy. METHODS: A retro-
spective study was conducted on a general sample of 4.974
patients, to whom an oral blood glucose lowering drug, a serum
lipid reducing agent and an antihypertensive drug had been pre-
scribed at least once during the observation period (2001–2003).
An equal sized control group (matched by sex and age) and a
sub-sample of 1.401 patients from the general sample (actual
consumers of the above prescribed drugs at least once in each of
the observational years) were also used. The general and sub-
sample showed no considerable differences in the primary out-
comes. All data was obtained from a Northern Local Health Unit
database. The prospective was the Italian NHS’s point of view.
The speciﬁc costs of the MS (drugs and hospitalisation) were cal-
culated as incremental costs, comparing the affected patients
(study group) to the general population (control group).
RESULTS: The Metabolic Syndrome affects both males (49.5%,
mean age 64.6) and females (50.5%, mean age 68.2). Yearly
mortality among patients with MS does not differ from mortal-
ity in the general population. All the costs in the study group
were signiﬁcantly higher than the corresponding costs in the
control group. The total average cost per year for a patient with
MS was estimated at €1522 (drugs: €558; hospitalisation: €964),
versus the lower corresponding estimation for the general 
population at €361 (drugs: €155; hospitalisation: €206). So, on
a yearly and per capita basis, the incremental cost of the meta-
bolic syndrome amounts to €1161.Mortality and age were
shown to be the major cost drivers. CONCLUSIONS: To the
NHS in Italy the cost for MS might be as high as €670 million
a year (0.9% of the total public health expenditure).
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OBJECTIVES: To assess the long-term cost-effectiveness of titra-
tion from initial doses of rosuvastatin (RSV) and generic sim-
vastatin (SIM). METHODS: Efﬁcacy data from the STELLAR
clinical trial (TC, HDL-C, and TG) were used as input to the
model. Markov models ran in 4-year cycles for 20 years, from
age 55 to 76 years to predict primary and secondary CHD based
on Framingham risk equations in four gender/risk cohorts. In
year one quarterly titration up to a maximum dose of 40mg
(RSV) or 80mg (SIM) was based on a total cholesterol (TC)
target of 5mmol/l. Risk was calculated using the average TC:
HDL-C ratio of 1000 simulated patients, with adjustment for
Framingham’s hypothesised over-prediction of UK risk. RSV and
generic SIM prices for September 2004 and recent UK CHD
event cost data were applied. Relative mortality risks and health-
state utilities were used to derive quality-adjusted life years
(QALYs). Discounting was performed at 3.5% (costs and out-
comes). RESULTS: The STELLAR trial found RSV 10mg
lowered total cholesterol signiﬁcantly more than SIM 10–40mg
(-32.9% vs. -20.3%, -25.7%, 27.9%, respectively), and RSV
20mg lowered total cholesterol signiﬁcantly more than SIM 
80mg (-37.6% vs. -32.9%). Based on this model less CHD
events and deaths are expected among patients on RSV com-
pared with SIM. Hence RSV delivers more QALYS at an accept-
able cost per patient, e.g. £3458 per QALY for high-risk males
compared with SIM. Insensitivity analysis when generic SIM is
priced at zero, the cost per QALY gained for RSV ranged from
£11,169 (male high risk) to £21,752 (female base case). CON-
CLUSIONS: More CHD events are likely to be avoided using
RSV than SIM. RSV will be a cost-effective strategy, as deﬁned
by UK NICE thresholds for cost per QALY gained, even as the
generic SIM price approaches zero.
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OBJECTIVES: To understand the patterns of aspirin utilization
among users of Nonsteroidal Anti-Inﬂammatory Drugs
(NSAIDs) with varying cardiovascular risk proﬁles. METHODS:
A telephone survey was completed using a large health beneﬁts
company population. The survey consisted of 10-items used to
characterize aspirin consumption and identify motivation for 
utilization. Subjects were randomly selected from a dataset of
members aged 18 and older, who had an NSAID prescription
claim between April 1, 2003 and June 30, 2003, while main-
taining continuous plan enrollment during a 24-month period.
Subjects were also required to maintain chronic NSAID utiliza-
tion, deﬁned as at least a 90 days’ supply during a 12-month
period. Study subjects were stratiﬁed based upon their NSAID
utilization into: 1) cox-II selective inhibitors; 2) non-selective
NSAIDs (excluding naproxen); and 3) naproxen. Subjects were
further stratiﬁed based upon the presence or absence of risk
factors associated with cardiovascular events. RESULTS: The
study population consisted of 1250 subjects, of which 52.3%
were treated with non-selective NSAIDs, 19.4% with naproxen,
and 28.3% with cox-II inhibitors. In total, 77.1% of the popu-
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lation had risk factors associated with cardiovascular events. No
signiﬁcant difference (P = 0.6945) was found in the proportion
of subjects using aspirin among the non-selective NSAID,
naproxen, and cox-II cohorts, with 46.8%, 48.8%, and 49.4%,
respectively. Likewise, no signiﬁcant differences were found
among the treatment cohorts with respect to: strength, frequency,
and duration of aspirin use (P = 0.3840, P = 0.8088 and P =
0.6838, respectively). Finally, no signiﬁcant difference (P =
0.2778) was found in the proportion of subjects using aspirin
among those with risk factors for cardiovascular events versus
those without. CONCLUSIONS: Unexpectedly, these results
indicate that aspirin utilization, strength, frequency, and dura-
tion are independent of both subjects’ cardiovascular risk proﬁle
(i.e. risk vs. no risk) and the NSAID class utilized (i.e. selective
vs. nonselective).
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OBJECTIVE: Randomized, controlled trials (RCT’s) are consid-
ered to be the gold standard of scientiﬁc evidence to assess safety
and effectiveness of cardiovascular devices. However, RCT use
is challenging to implement in certain device trials, due to logis-
tical and ethical reasons. The FDA understands that assessment
of device technologies must balance the competing demands of
maximizing scientiﬁc validity against the practical realities of
performing (and effectively completing) these clinical studies.
Hence, non-randomized clinical trials are sometimes used in
device evaluation. Propensity score analysis, as an alternative to
traditional covariate adjustment methods, has been increasing in
popularity as a technique to control for baseline differences
between treatment groups in non-randomized cardiovascular
device studies. METHODS: Propensity scores provide a conve-
nient methodology for covariate adjustment when multiple
covariates are involved. However, propensity score methodology
does not eliminate many of the scientiﬁc limitations of non-
randomized studies compared to RCT’s, and should not be
viewed as a substitute for performing a randomized study. In
using propensity score modeling, a full pre-speciﬁcation of
covariates to be included and the model to be used is recom-
mended to minimize the concern of bias introduced by post hoc
model development. RESULTS: Furthermore, sensitivity analy-
sis should be performed to demonstrate the robustness of study
outcome in the face of hidden bias due to unmeasured or
unquantiﬁable covariates. Lastly, it is recommended that con-
ventional covariate adjustment as well as propensity score
adjustment should be performed to demonstrate consistency of
outcomes between techniques. CONCLUSION: Propensity score
methodology has increased in popularity for covariate adjust-
ment in non-randomized cardiovascular device studies. However,
there are limitations to this methodology, which must be fully
appreciated to avoid erroneous inferences from study data. 
Randomized trials are still preferred and strongly encouraged
whenever possible, especially for the evaluation of novel cardio-
vascular devices.
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OBJECTIVES: The Eplerenone Post-Acute Myocardial Infarc-
tion Heart Failure Efﬁcacy and Survival Study (EPHESUS)
showed that the addition of eplerenone to optimal medical
therapy reduced both morbidity and mortality in patients with
acute myocardial infarction (AMI) complicated by left ventricu-
lar dysfunction and heart failure whilst reducing the number and
duration of heart failure re-hospitalisations. A budget impact
model was developed to estimate the effects of adding eplerenone
to standard care in the UK National Health Service (NHS).
METHODS: Within the model the efﬁcacy of eplerenone is
based on the EPHESUS study. This is applied to UK epidemio-
logical data on the incidence of AMI, proportion of survivors
developing heart failure and their prognosis. UK drug acquisi-
tion costs and NHS hospital inpatient costs and average length
of stay for England are included. All costs are expressed in
pounds sterling. The model estimates the incremental costs and
beneﬁts of adding eplerenone to standard care in heart failure
resulting from AMI from the perspective of NHS health care
decision makers over a three-year period. Input variables include
population, incidence of AMI and annual rate of eplerenone
uptake. RESULTS: If all eligible patients are treated in an NHS
Primary Care Trust of population 250,000, the estimated cost
per life year saved is 6,701 pounds in year three, for an addi-
tional expenditure of £256,959. This level of treatment results
in a reduction of 101 bed days for re-hospitalisations due to
heart failure, at a cost per bed day avoided of €1207. CON-
CLUSIONS: With hospital inpatient care the biggest single
health care cost in heart failure, reduction in hospitalisation is a
key priority within the UK NHS. Models such as the one
described here enable the economic consequences of using a new
drug to be identiﬁed and clarify the role of drug treatment in
delivering NHS priorities.
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OBJECTIVES: To estimate incremental cost-effectiveness of
adding a GPIIb/IIIa inhibitor (eptiﬁbatide) to percutaneous coro-
nary intervention (PCI) and standard medical management
(MM) versus PCI + MM alone in Poland for patients with non-
ST-elevation myocardial infarction (NSTEMI) at high risk of
recurrent ischemia or cardiovascular death. METHODS: A
Markov model was constructed to estimate the additional costs
and beneﬁts of a GPIIb/IIIa inhibitor on top of standard care.
The model has 4 disease states (no event, post-ischemia, post-
MI, death) and two tunnel states (refractory ischemia, non-fatal
MI). PCI + MM include beta blockers, ACE inhibitors, aspirin,
heparin and clopidogrel. The model takes the Polish national
health payer perspective and runs for the expected lifetime of the
patient. The effectiveness parameters were taken from a 6-month
GPIIb/IIIa clinical trial and extrapolated to 45 years with an esti-
mated Weibull function. Event and follow-up costs are based on
assumed treatment patterns. The results of the model were
expressed in total (discounted) costs and life years per patient,
and incremental cost per life year gained. A series of one-way
sensitivity analyses has been conducted on the major model
inputs. RESULTS: The lifetime discounted costs for the base case
analysis are 13,856 PLN per patient for the PCI + MM group
and 15,570 PLN for the eptiﬁbatide group (a difference of 1714
PLN). The use of eptiﬁbatide provides an additional average of
0.05 year of life per patient compared with PCI + MM. The
incremental cost effectiveness ratio for the lifetime model, with
